Novartis renews drug donation of Egaten ® (triclabendazole) until 2022

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) to extend its drug donation for Egaten® (triclabendazole) until 2022. Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news